- Home
- PMTS vs EDIT Comparison
PMTS vs EDIT Comparison
Compare PMTS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMTS
- EDIT
- Stock Information
- Founded
- PMTS 2007
- EDIT 2013
- Country
- PMTS United States
- EDIT United States
- Employees
- PMTS N/A
- EDIT N/A
- Industry
- PMTS Finance Companies
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMTS Finance
- EDIT Health Care
- Exchange
- PMTS Nasdaq
- EDIT Nasdaq
- Market Cap
- PMTS 236.9M
- EDIT 263.7M
- IPO Year
- PMTS 2015
- EDIT 2016
- Fundamental
- Price
- PMTS $18.75
- EDIT $2.44
- Analyst Decision
- PMTS Strong Buy
- EDIT Buy
- Analyst Count
- PMTS 4
- EDIT 12
- Target Price
- PMTS $36.75
- EDIT $6.20
- AVG Volume (30 Days)
- PMTS 36.8K
- EDIT 2.7M
- Earning Date
- PMTS 08-08-2025
- EDIT 08-11-2025
- Dividend Yield
- PMTS N/A
- EDIT N/A
- EPS Growth
- PMTS 1.33
- EDIT N/A
- EPS
- PMTS 1.58
- EDIT N/A
- Revenue
- PMTS $491,426,000.00
- EDIT $35,837,000.00
- Revenue This Year
- PMTS $14.61
- EDIT N/A
- Revenue Next Year
- PMTS $12.49
- EDIT N/A
- P/E Ratio
- PMTS $11.86
- EDIT N/A
- Revenue Growth
- PMTS 12.81
- EDIT N/A
- 52 Week Low
- PMTS $18.32
- EDIT $0.91
- 52 Week High
- PMTS $35.19
- EDIT $5.45
- Technical
- Relative Strength Index (RSI)
- PMTS 26.47
- EDIT 43.06
- Support Level
- PMTS $20.07
- EDIT $2.66
- Resistance Level
- PMTS $21.57
- EDIT $3.58
- Average True Range (ATR)
- PMTS 0.77
- EDIT 0.28
- MACD
- PMTS -0.24
- EDIT -0.11
- Stochastic Oscillator
- PMTS 10.87
- EDIT 5.79
About PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.